Edition:
United States

Applied Genetic Technologies Corp (AGTC.OQ)

AGTC.OQ on NASDAQ Stock Exchange Global Market

3.55USD
1:59pm EST
Change (% chg)

$-0.08 (-2.07%)
Prev Close
$3.62
Open
$3.60
Day's High
$3.60
Day's Low
$3.55
Volume
3,339
Avg. Vol
20,241
52-wk High
$10.15
52-wk Low
$3.28

Chart for

About

Applied Genetic Technologies Corporation is a clinical-stage biotechnology company. The Company develops gene therapy products designed to manage the lives of patients with severe diseases in ophthalmology. As of March 31, 2016, its product candidates included treatments for X-linked retinoschisis (XLRS), over two forms of... (more)

Overall

Beta: 1.59
Market Cap(Mil.): $65.59
Shares Outstanding(Mil.): 18.09
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 196.13 16.04
EPS (TTM): -- -- --
ROI: -- -11.69 35.70
ROE: -- -36.44 15.40

BRIEF-Applied Genetic posts qtrly ‍net loss of $0.08​ per share

* Company expects total cash, cash equivalents, and investments as of june 30, 2018 to be between $85 and $100 million​

Nov 07 2017

BRIEF-Applied Genetic Technologies reports Q4 revenue of $8.3 mln

* Q4 earnings per share view $0.06 -- Thomson Reuters I/B/E/S

Sep 13 2017

BRIEF-AGTC appoints Matthew Feinsod, M.D. as interim chief medical officer

* AGTC appoints Matthew Feinsod, M.D. as interim chief medical officer

Sep 05 2017

BRIEF-Applied Genetic Technologies partners with the Foundation Fighting Blindness

* AGTC and The Foundation Fighting Blindness announce partnership agreement Source text for Eikon: Further company coverage:

Aug 15 2017

BRIEF-AGTC files investigational new drug application for treatment of x-linked retinitis pigmentosa

* AGTC files investigational new drug application for the treatment of x-linked retinitis pigmentosa caused by mutations in the RPGR gene

Aug 10 2017

BRIEF-AGTC announces FDA orphan drug designation for therapy to treat X-linked retinitis pigmentosa

* AGTC announces U.S. FDA orphan drug designation for gene therapy to treat X-linked retinitis pigmentosa Source text for Eikon: Further company coverage:

Aug 03 2017

BRIEF-AGTC appoints William Sullivan as chief financial officer

* AGTC appoints William Sullivan as chief financial officer, Andrew Ashe named general counsel

Aug 02 2017

Earnings vs. Estimates